tiprankstipranks
Trending News
More News >

Sumitomo Pharma Highlights Independence Amid Parent Company Ties

Story Highlights
Sumitomo Pharma Highlights Independence Amid Parent Company Ties

Don’t Miss TipRanks’ Half-Year Sale

Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an update.

Sumitomo Pharma Co., Ltd. announced details about its relationship with its parent company, Sumitomo Chemical Co., Ltd., which holds a 51.78% voting interest. The announcement highlights the company’s operational independence, despite its integration into the parent company’s corporate group. The collaboration includes joint ventures in regenerative medicine and shared resources, but the company maintains managerial independence, with no limitations imposed on its business activities by the parent company.

The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.

More about Sumitomo Dainippon Pharma Co

Sumitomo Pharma Co., Ltd. is a core member of Sumitomo Chemical Co., Ltd.’s corporate group, focusing on the ethical drugs segment within the pharmaceutical industry. The company is involved in the development and commercialization of regenerative medicine and cell therapy products, and it collaborates closely with its parent company in various operational aspects, including leasing assets and procuring raw materials.

Average Trading Volume: 11,477,283

Technical Sentiment Signal: Buy

Current Market Cap: Yen372.3B

For an in-depth examination of 4506 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1